Europe Infectious Disease Immunoassay Testing Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Europe Infectious Disease Immunoassay Testing Market Overview

The Europe infectious disease immunoassay testing market reached a value of approximately USD 2.80 Billion in 2025. The market is expanding steadily, supported by increasing infectious disease surveillance, advanced laboratory infrastructure, and growing adoption of automated diagnostic technologies. Immunoassay testing plays a vital role in the rapid detection of viral, bacterial, fungal, and parasitic infections across clinical and public health settings. Continuous technological advancements, stringent regulatory standards, and rising demand for high-throughput diagnostic solutions are driving innovation. Strong investments in healthcare modernization and infectious disease preparedness continue supporting long-term market development across Europe.

Europe Infectious Disease Immunoassay Testing Market Growth Analysis and Key Influencers

Europe Infectious Disease Immunoassay Testing Market Dynamics

This section analyzes factors influencing the market, including infectious disease prevalence, diagnostic innovation, immunoassay technology advancements, regulatory frameworks, laboratory modernization, reimbursement policies, strategic collaborations, investment trends, and healthcare infrastructure development.

Europe Infectious Disease Immunoassay Testing Market Growth Drivers

Product Innovation Driving Europe Infectious Disease Testing Market Expansion

Growing adoption of automated diagnostics and increasing implementation of the IVDR framework are strengthening diagnostic innovation across Europe. Their impact is expected to accelerate market development throughout the forecast period. For instance, in March 2026, bioMérieux received IVDR CE marking for two BIOFIRE® SPOTFIRE® respiratory and sore throat panels, enabling near-patient testing across European healthcare settings. The approval is expected to improve accessibility, strengthen decentralized diagnostics, and support broader adoption of immunoassay testing solutions.

Europe Infectious Disease Immunoassay Testing Market Restraints

Regulatory Complexity Slows European Infectious Disease Immunoassay Product Development Progress

Strict conformity assessments and heavy documentation requirements continue to challenge diagnostic manufacturers entering European markets. For instance, in May 2026, MedTech Europe reported that IVDR implementation had created slow and unpredictable assessment timelines, high administrative burdens, and differing interpretations among Member States. During the forecast period, these market restraints may delay new immunoassay launches, raise certification expenses, reduce product availability, and place smaller developers under greater financial pressure when seeking approval for infectious disease testing systems across the region successfully.

Regulatory Compliance Challenges Influencing European Diagnostic Market Development

Expanding infectious disease surveillance and growing laboratory modernization continue supporting diagnostic demand; however, evolving regulatory requirements and IVDR compliance remain operational challenges. Their impact is expected to influence commercialization during the forecast period. For instance, in July 2026, Roche received CE Mark for its Elecsys IGRA TB blood test, requiring laboratories to adapt workflows while meeting new regulatory standards for implementation. This development highlights compliance considerations affecting Diagnostic Laboratories across Europe.

Europe Infectious Disease Immunoassay Testing Market Opportunities

Host Response Assays Expand European Infectious Disease Testing Commercial Potential

Growing antimicrobial resistance concerns and demand for faster treatment decisions are encouraging adoption of host-response testing. For instance, in April 2026, Beckman Coulter introduced the CE-marked Access MeMed BV assay in Europe, enabling laboratories to distinguish bacterial from viral infections in about 20 minutes on established immunoassay analyzers. During the forecast period, this development may create market opportunities by supporting antibiotic stewardship, expanding emergency testing, improving clinical decision-making, and increasing demand for rapid infection classification more widely across European hospitals.

Europe Infectious Disease Immunoassay Testing Market Trends

Automated Dengue Detection Shapes European Infectious Disease Immunoassay Adoption Direction

Rising dengue importation risks and demand for outbreak-ready laboratory capacity are encouraging automated antigen testing. For instance, in October 2025, Roche received the CE Mark for the Elecsys Dengue Ag test, a fully automated immunoassay that detects acute dengue infection and delivers results in 18 minutes. During the forecast period, this launch may reinforce market trends toward high-throughput platforms, faster turnaround, improved traceability, and broader use of automated infectious disease assays in European laboratories managing emerging travel-related infections more effectively.

Europe Infectious Disease Immunoassay Testing Market Share

Diagnostic Laboratories Likely to Dominate the Market Segment by End User

Diagnostic laboratories remain central to infectious disease detection because they provide specialized expertise, automated testing platforms, and high-volume analytical capabilities. Their role continues expanding alongside increasing laboratory modernization efforts across Europe. Diagnostic Laboratories held about 58% market share in the historical period and are likely to dominate the market during the forecast period, supported by growing testing demand, infrastructure investments, and advanced laboratory technologies.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Europe Infectious Disease Immunoassay Testing Market Analysis by Region

Germany maintains a strong position within the European diagnostics landscape through its advanced healthcare infrastructure, established biotechnology industry, and extensive laboratory network. Continuous investment in infectious disease preparedness further supports market development. Germany held about 23% market share in the historical period and is likely to dominate the market during the forecast period, supported by technological innovation, healthcare expenditure, and diagnostic research capabilities.

Leading Players in the Europe Infectious Disease Immunoassay Testing Market

Europe Infectious Disease Immunoassay Testing Market Segmentation

Key Questions Answered in the Europe Infectious Disease Immunoassay Testing Market Report

• What was the Europe infectious disease immunoassay testing market value in 2025?
• What is the Europe infectious disease immunoassay testing market forecast outlook for 2026-2035?
• What major factors aid the demand for the Europe infectious disease immunoassay testing market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Europe infectious disease immunoassay testing market trends?
• Which product and service segment is expected to dominate the market?
• Which type of testing segment is expected to hold the largest market share?
• Which sample type is expected to account for the highest market share?
• Which disease type is expected to account for the highest market share?
• Which technology is expected to account for the highest market share?
• Which application is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the Europe infectious disease immunoassay testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with diagnostic manufacturers, laboratory managers, microbiologists, clinicians, regulatory specialists, and professionals involved in infectious disease immunoassay testing across Europe.
• Secondary Research: Sources included company announcements, CE-marking updates, technical documents, MedTech Europe publications, regulatory reports, scientific journals, and peer-reviewed studies on testing.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.